Related Experiment Video

Updated: Mar 2, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

Stat3 inhibitor abrogates the expression of PD-1 ligands on lymphoma cell lines

Chaoya Ma1, Hasita Horlad1, Cheng Pan1

  • 1Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University.

Journal of Clinical and Experimental Hematopathology : JCEH
|May 13, 2017
PubMed

Insights

A Stat3 inhibitor, WP1066, effectively reduced programmed death-ligand 1/2 (PD-L1/2) expression in lymphoma cell lines. This finding suggests WP1066 could enhance immunotherapy for advanced lymphoma patients.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Immune checkpoint molecules like PD-1 are crucial for anti-tumor immunity.
  • Programmed death-ligand 1/2 (PD-L1/2) expression was previously found on adult T-cell leukemia/lymphoma (ATL-T) and B-cell lymphoma (SLVL) cell lines.

Purpose of the Study:

  • To investigate if the Stat3 inhibitor WP1066 could abrogate PD-L1/2 expression in lymphoma cell lines.
  • To assess the impact of WP1066 on lymphoma cell growth and apoptosis.

Main Methods:

  • Incubation of lymphoma cell lines (ATL-T, SLVL, HKBML) with the Stat3 inhibitor WP1066.
  • Assessment of lymphoma cell growth, apoptosis, and PD-L1/2 expression levels.

Main Results:

  • WP1066 treatment inhibited lymphoma cell growth and induced apoptosis.
  • WP1066 significantly abrogated PD-L1/2 expression in ATL-T, SLVL, and human brain malignant lymphoma (HKBML) cell lines.

Conclusions:

  • Stat3 inhibition by WP1066 effectively reduces PD-L1/2 expression in lymphoma cells.
  • WP1066 shows potential as an adjunct therapy for advanced lymphoma, enhancing immunotherapy outcomes.
Keywords:
PD-L1PD-L2Stat3lymphoma

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.9K